Neocor Therapeutics
We are currently developing a novel gene therapy approach targeting ischemic and rare genetic cardiac diseases, and moving from lab preclinical trials to regulatory trials. The Company was founded in October and has received strong traction since inception. We will be looking to strengthen our human and financial ressources in the coming month in order to start the regulatory pre clinical trials.
7-day free trial · no credit card
Verified contacts
4
available on Kipplo
LinkedIn employees
5
1 to 10 range
Open roles
—
no listings
Distinct roles
3
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 4 verified contacts at Neocor Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
4 contacts with verified email or phone · masked until revealed.
- FH
Fabien Hubert
Head of R & d and Preclinical Development · Research & Development
EmailPhone - LB
Laetitia Bouchard
Étudiant En Doctorat · Research & Development
EmailPhone - MM
Matthieu Metz
Chief Executive Officer · General Business & Management
EmailPhone
Showing 3 of 4 verified contacts
Top roles at Neocor Therapeutics
3 distinct titles indexed · top 3 shown.
- 2chief executive officer
- 1head of r & d and preclinical development
- 1étudiant en doctorat
Sign up to unlock all 4 contacts at Neocor Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 4 verified contacts at Neocor Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.